At the heart of innovation is T-win®, a groundbreaking vaccine platform that could change how we treat cancer.

A Texas A&M scientist is using gene editing and other bioengineering to attack mosquito-borne diseases such as malaria, ...

Population model successfully developed to characterize BI-1910 pharmacokinetics and pharmacodynamics across a broad range of dosesModel will support dose selection for upcoming studies; Phase 2a as ...

Ministry of Science & Technology observed Swachhata Pakhwada 2025 from 1st May to 15th May 2025 at its Headquarters in New Delhi and across all its Autonomous Institutions (AIs) and Public Sector Unde ...

On June 5, 2025, the House Science and Technology Subcommittees on Energy and on Research and Technology will hold a joint ...

By a News Reporter-Staff News Editor at Health Policy and Law Daily-- A new study finds that CivicaScript, a not-for-profit drug manufacturer in the US, can reliably supply essential generic medicines ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the ...

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use new ...

PDS Biotechnology ( ($PDSB) ) has shared an update. On June 2, 2025, PDS Biotechnology Corporation announced the publication of three Versamune® ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

MAIA Biotechnology, Inc. (NYSE American ... efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of ...